Gilead Sciences (Gilead Sciences) Total Liabilities : $39,376 Mil (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Gilead Sciences Total Liabilities?

Gilead Sciences's Total Liabilities for the quarter that ended in Dec. 2023 was $39,376 Mil.

Gilead Sciences's quarterly Total Liabilities declined from Jun. 2023 ($41,244.00 Mil) to Sep. 2023 ($40,132.00 Mil) and declined from Sep. 2023 ($40,132.00 Mil) to Dec. 2023 ($39,376.00 Mil).

Gilead Sciences's annual Total Liabilities declined from Dec. 2021 ($46,888.00 Mil) to Dec. 2022 ($41,962.00 Mil) and declined from Dec. 2022 ($41,962.00 Mil) to Dec. 2023 ($39,376.00 Mil).

Gilead Sciences Total Liabilities Historical Data

The historical data trend for Gilead Sciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Total Liabilities Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

38,977.00

50,186.00

46,888.00

41,962.00

39,376.00

Gilead Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															41,962.00	40,937.00	41,244.00	40,132.00	39,376.00

Gilead Sciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Gilead Sciences's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11280	+	(23189	+	3319
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1588	+	0)
	=	39,376

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	62125	-	22749
	=	39,376

Gilead Sciences's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11280	+	(23189	+	3319
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1588	+	0)
	=	39,376

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	62125	-	22749
	=	39,376

Gilead Sciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (Gilead Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Executives

Andrew D Dickinson	officer: EVP, Chief Financial Officer	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Johanna Mercier	officer: Chief Commercial Officer	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey	officer: Chief Medical Officer	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson	officer: SVP, Controllership	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong	officer: SVP, Controller & CAO	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman	officer: EVP, Corporate Affairs & GC	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher	officer: EVP, Gen Counsel & Corp Sec	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Jeffrey Bluestone	director	C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Anthony Welters	director
Javier Rodriguez	director	601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan	director	2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson	director	C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold	director	C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley	director	UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711